Kisplyx

Lenvatinib, the active ingredient in Kisplyx, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma in adult patients. The drug works by blocking multiple receptor tyrosine kinases involved in tumor angiogenesis and cell proliferation.

GNH USA supplies Kisplyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to stringent regulatory requirements and batch‑to‑batch consistency.

Kisplyx (lenvatinib) targets key signaling pathways in several solid tumours, providing therapeutic benefit across multiple cancer types.

- Differentiated thyroid cancer: improves progression‑free survival by inhibiting tumor growth and angiogenesis. - Renal cell carcinoma: reduces tumor burden and delays disease progression in advanced cases. - Hepatocellular carcinoma: slows disease advancement when used in combination with other agents. - Endometrial carcinoma: enhances response rates in patients with advanced disease.

Lenvatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure commonly observed. - Diarrhea: frequent loose stools. - Fatigue: persistent tiredness. - Nausea: feeling of sickness. - Decreased appetite: reduced desire to eat. - Weight loss: unintended loss of body weight.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury. - Arterial thromboembolism: clot formation in arteries. - Severe hemorrhage: significant bleeding events. - Gastrointestinal perforation or fistula formation. - Life‑threatening hypertension requiring urgent treatment.

When prescribing Kisplyx, clinicians should observe several safety measures to minimise risk.

- Monitor blood pressure: check regularly for hypertension, a frequent effect. - Assess liver function: perform baseline and periodic liver enzyme tests. - Evaluate for proteinuria: urine analysis should be performed periodically. - Review concomitant anticoagulant use: increased bleeding risk may occur. - Adjust dose in renal impairment: consider reduced dosing in patients with decreased renal function. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lenvatinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lenvatinib plasma levels, increasing toxicity. - Strong CYP3A4 inducers (e.g., rifampicin): may lower exposure, reducing effectiveness. - Anticoagulants (e.g., warfarin): heightened risk of severe bleeding.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: blood pressure control may be affected; monitor and adjust doses. - Oral contraceptives: efficacy may be reduced; consider alternative contraception.